Accession Number : ADA469431


Title :   Vital: Vanguard Investigations of Therapeutic Approaches to Lung Cancer


Descriptive Note : Annual rept. 15 Dec 2005-14 Dec 2006


Corporate Author : TEXAS UNIV AT HOUSTON


Personal Author(s) : Hong, Waun K ; Lotan, Reuben ; Stewart, David


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/a469431.pdf


Report Date : Jan 2007


Pagination or Media Count : 341


Abstract : The VITAL Research Program will provide a better understanding of the cellular and molecular processes that drive lung tumorigenesis so that an accurate risk model for recurrence and/or the development of the second primary tumor can be developed, and the biologic agents most effect in reducing these events in the group of high-risk patients can be identified. Until this time, our clinical trails (Vanguard and Celecoxib trials) are ongoing and Tarceva trial will be opened in January 2007. The research projects are proceeding well as proposed, producing valuable findings with cell lines, and will validate these results using the clinical samples obtained from the VITAL trials in the coming years.


Descriptors :   *BIOLOGICAL AGENTS , *BREAST CANCER , *LUNG CANCER , RISK , MODELS , MOLECULES , CLINICAL TRIALS , CLINICAL MEDICINE , THERAPY , PATIENTS , CELLS(BIOLOGY) , CYTOLOGY


Subject Categories : Medicine and Medical Research
      Chemical, Biological and Radiological Warfare


Distribution Statement : APPROVED FOR PUBLIC RELEASE